1. Illumina will announce Q2 2025 results on July 31, 2025. 2. CEO Jacob Thaysen and CFO Ankur Dhingra will lead a conference call. 3. Live webcast available via Illumina's website for interested parties. 4. Replay of the call will be accessible for 30 days post-event. 5. Illumina focuses on DNA sequencing and array-based technologies for health improvement.
Upcoming earnings reports often drive stock prices. If results show positive growth, ILMN's stock could rise, similar to past earnings boosts in 2022.
Upcoming earnings results are crucial for investor expectations and market performance.
Investor sentiment may shift quickly following earnings results. Immediate reactions to quarterly performance can significantly affect stock price.
Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025.
On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q2-2025.open-exchange.net/registration. To ensure timely connection, please join at least ten minutes before the scheduled start of the call.
A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Brian Blanchett
+1.858.291.6421
[email protected]
Christine Douglass
[email protected]
SOURCE Illumina, Inc.